Topics
Gliomas | Diagnosis | Proton emission tomography
Home > Publications > Topics > Gliomas > Diagnosis > Proton emission tomography
Albert NL, Galldiks N, Ellingson
BM, van den Bent MJ, Chang SM, Cicone F, de Groot J, Koh ES, Law
I, Le Rhun E, Mair MJ, Minniti G, Rudà R, Scott AM, Short
SC, Smits M, Suchorska B, Tolboom N, Traub-Weidinger T, Tonn JC,
Verger A, Weller M, Wen PY, Preusser M.
PET-based
response assessment criteria for diffuse gliomas (PET RANO 1.0): a
report of the RANO group.
Lancet
Oncol. 2024 Jan
2;25(1):e29-e41. doi:
10.1016/S1470-2045(23)00525-9. PMID:
38181810. Review, Guidelines˰ ˍ
Yu P, Wang Y, Su F, Chen
Y.
Comparing
[18F]FET PET and [18F]FDOPA PET for glioma recurrence diagnosis: a
systematic review and meta-analysis.
Front
Oncol. 2024 Jan
10;13:1346951. doi:
10.3389/fonc.2023.1346951. PMID:
38269019. Review, Meta-analysis. ˍ
Zinsz A, Pouget C, Rech F, Taillandier L, Blonski M, Amlal S,
Imbert L, Zaragori T, Verger A.
The
role of [18 F]FDOPA PET as an adjunct to conventional MRI in the
diagnosis of aggressive glial lesions.
Eur
J Nucl Med Mol Imaging. 2024 Apr 19. doi:
10.1007/s00259-024-06720-y. PMID:
38637354. Observational study˰
ˍ
McBriar JD, Shafiian N, Scharf S, Boockvar JA, Wernicke AG.
Prostate-Specific Membrane Antigen Use
in Glioma Management: Past, Present, and Future.
Clin
Nucl Med. 2024 Jul 3. doi:
10.1097/RLU.0000000000005365. PMID:
38968568. Review˰ ˍ
Galldiks N, Lohmann P, Friedrich M,
Werner JM, Stetter I, Wollring MM, Ceccon G, Stegmayr C, Krause S,
Fink GR, Law I, Langen KJ, Tonn JC.
PET
imaging of gliomas: Status quo and quo vadis?
Neuro
Oncol. 2024 Jul
6:noae078. doi:
10.1093/neuonc/noae078. PMID:
38970818. Review˰ ˍ
Robert JA, Leclerc A, Ducloie M, Emery E, Agostini D, Vigne J.
Contribution of [18F]FET
PET in the Management of Gliomas, from Diagnosis to Follow-Up: A
Review.
Pharmaceuticals
(Basel). 2024 Sep 18;17(9):1228. doi:
10.3390/ph17091228. PMID:
39338390. Review. ˍ
Azam A, Kurbegovic S, Carlsen EA, Andersen TL, Larsen VA, Law I,
Skjøth-Rasmussen J, Kjaer A.
Prospective
phase II trial of [68Ga]Ga-NOTA-AE105
uPAR-PET/MRI in patients with primary gliomas: Prognostic value
and Implications
for uPAR-targeted Radionuclide Therapy.
EJNMMI
Res. 2024 Oct 29;14(1):100. doi:
10.1186/s13550-024-01164-9. PMID:
39472354. Interventional study. ˍ